Skip to main content

Latest data from the ABCD worldwide EndoBarrier registry presented at EASD in Stockholm



During the week of the 19th to 23rd September 2022, the latest data from the ABCD worldwide EndoBarrier registry were presented as an oral presentation to a packed audience in a session chaired by Prof Les Zech Czupryniaz entitled '' fighting diabetes with tubes, scanners, and catheters" The registry now contains data from 1022 patient's from 34 centres in 10 countries worldwide and demonstrated that EndoBarrier is associated with major improvements in weight, HbA1c, blood pressure and cholesterol. It was noteworthy that the higher the HbA1c the greater the fall such that the if baseline HbA1c ≥ 86 mmol/mol (≥ 10%) there was a fall of 34.9 mmol/mol (3.2%).  The serious adverse event rate was 4.2% and it was noteworthy that the rate of hepatic abscess was 1.1% noticeably different from the 3.5% found in the FDA pivotal study which led to that study being halted. The presentation (12½ minutes long) including a very informative question and answer session and the viewing of an actual EndoBarrier can be seen at the following link: